Mitsubishi UFJ Asset Management Co. Ltd. Makes New Investment in Twist Bioscience Corporation $TWST

Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 27,485 shares of the company’s stock, valued at approximately $2,828,000.

Several other large investors have also recently added to or reduced their stakes in TWST. William Blair Investment Management LLC increased its stake in shares of Twist Bioscience by 43.7% in the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after acquiring an additional 1,812,146 shares during the last quarter. EdgePoint Investment Group Inc. lifted its holdings in Twist Bioscience by 31.7% in the 4th quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock worth $170,590,000 after purchasing an additional 1,295,672 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Twist Bioscience by 151.5% in the third quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock worth $50,479,000 after buying an additional 1,080,722 shares during the last quarter. ARK Investment Management LLC lifted its position in Twist Bioscience by 12.4% during the 4th quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock worth $239,787,000 after acquiring an additional 832,687 shares during the last quarter. Finally, Balyasny Asset Management L.P. lifted its position in shares of Twist Bioscience by 934.0% during the 2nd quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company’s stock worth $23,113,000 after purchasing an additional 567,481 shares during the last quarter.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $145.59 on Friday. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $145.93. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $9.13 billion, a P/E ratio of -65.58 and a beta of 2.14. The business has a 50-day moving average of $100.69 and a 200-day moving average of $70.33.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The firm had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. During the same quarter last year, the business posted $0.33 earnings per share. The company’s revenue for the quarter was up 23.2% on a year-over-year basis. On average, equities analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on TWST. Leerink Partners set a $110.00 price target on shares of Twist Bioscience in a report on Thursday, July 16th. Guggenheim boosted their price target on Twist Bioscience from $60.00 to $107.00 and gave the company a “buy” rating in a research note on Monday, June 29th. UBS Group set a $89.00 price objective on shares of Twist Bioscience in a research note on Monday, June 15th. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a report on Monday, August 3rd. Finally, Canaccord Genuity Group raised their price target on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $98.30.

Insiders Place Their Bets

In other Twist Bioscience news, CEO Emily M. Leproust sold 113,318 shares of Twist Bioscience stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $125.16, for a total value of $14,182,880.88. Following the sale, the chief executive officer owned 818,938 shares of the company’s stock, valued at $102,498,280.08. This trade represents a 12.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dennis Cho sold 14,205 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total value of $1,274,898.75. Following the completion of the sale, the insider directly owned 105,141 shares in the company, valued at approximately $9,436,404.75. This represents a 11.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 151,529 shares of company stock valued at $17,708,772 in the last quarter. 3.08% of the stock is owned by company insiders.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.